Clinical Trials
17 trialsNCT04901702 2026-05-19
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
St. Jude Children's Research Hospital
Phase 1/2 Recruiting
NCT06395103 2026-05-15
MK-9999-01A
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT04851119 2026-05-05
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Children's Oncology Group
Phase 1/2 Recruiting
NCT06721689 2026-04-15
PEEL-224
Children's Hospital of Philadelphia
Phase 1/2 Recruiting
NCT06607692 2026-04-14
LUPARPED
Fundación de investigación HM
Phase 1/2 Recruiting
NCT06465199 2026-04-13
Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
Milton S. Hershey Medical Center
Phase 1/2 Recruiting
NCT06541262 2026-04-09
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Milton S. Hershey Medical Center
Phase 1/2 Recruiting
NCT07502287 2026-03-30
DUAL-NK-NB
Beijing Biotech
Phase 1/2 Recruiting
NCT06625190 2026-03-11
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
University of Florida
Phase 1/2 Recruiting
NCT07399821 2026-02-10
GLOW-FISH
Princess Maxima Center for Pediatric Oncology
Phase 1/2 Recruiting
NCT05642455 2026-02-09
SPEARHEAD-3 Pediatric Study
USWM, LLC (dba US WorldMeds)
Phase 1/2 Recruiting
NCT05027386 2026-02-05
Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Pediatric Neuroblastoma: A Single-arm, Phase I/II,Multi-center, Clinical Study.
Sun Yat-sen University
Phase 1/2 Recruiting
NCT07334301 2026-01-12
BEACON2
University of Birmingham
Phase 1/2 Recruiting
NCT06803875 2025-12-26
Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma
Boston Children's Hospital
Phase 1/2 Recruiting
NCT05296564 2025-10-02
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
Hadassah Medical Organization
Phase 1/2 Recruiting
NCT04211675 2025-05-13
STING
Nationwide Children's Hospital
Phase 1/2 Recruiting
NCT06836505 2025-02-26
Safety and Efficacy of CAR-T Cell Therapy for Relapsed/refractory Neuroblastoma and Desmoplastic Small Round Cell Tumors: a Single-arm, Open-label Trial.
Sun Yat-sen University
Phase 1/2 Recruiting